Lymphoma – VJRegenMed

Safety and efficacy of LV20.19 CAR-T therapy in Richter’s transformation and R/R MCL

Anya Kerkache — Thu, 09 Mar 2023 11:31:47 +0000

Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, comments on the results of two studies evaluating the LV20.19 CAR-T product in patients with Richter’s transformation and in patients with heavily pretreated mantle cell lymphoma (MCL; NCT04186520). Out of the six patients with Richter’s transformation who were evaluated, four achieved a durable remission and the overall response rate (ORR) was 100%. Patients presented a unique toxicity profile, with a high incidence of hemophagocytic lymphohistiocytosis (HLH)-like toxicity. In MCL, eight of the 14 patients in the study met the primary endpoint, and the ORR at day 90 was 100%. This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL

Anya Kerkache — Thu, 09 Mar 2023 11:31:46 +0000

Nirav Shah, MD, Medical College of Wisconsin, Milwaukee, WI, gives an update on a Phase I study of rapcabtagene autoleucel in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Dr Shah explains that this next-generation CD19 CAR-T therapy has been manufactured using T-Charge, which allows this product to be manufactured faster than other CAR-T therapies, thus helping it to preserve T cell stemness, decrease the dose of infused CAR-Ts, and increase its overall quality. The study identified a safe dose level for further investigations and reported low rates of cytokine release syndrome (CRS). This interview took place at the 2023 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR® held in Orlando, FL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

The importance of managing hematologic toxicity associated with CAR-T therapy

Anya Kerkache — Wed, 08 Mar 2023 10:35:17 +0000

In this video, Marion Subklewe, MD, Ludwig-Maximilians University of Munich, Munich, Germany, comments on the importance of improving methods of assessing and managing hematologic toxicity associated with the use of CAR-T therapy. Prof. Subklewe also shares some insights into the novel CAR-HEMATOTOX risk stratification tool being evaluated in patients treated with CAR-T therapy for various hematological malignancies. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy

Anya Kerkache — Thu, 26 Jan 2023 12:12:01 +0000

Veit Buecklein, MD, LMU Munich, Munich, Germany, comments on real-world evidence comparing CD19 CAR-T cell therapy outcomes in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) in Europe and the US. Investigators observed significantly lower progression-free survival (PFS) in the European group, as well as significantly reduced radiographic response. Potential reasons for these differences included an adverse risk profile in European patients, logistical challenges resulting in longer vein-to-vein times, and the more frequent use of  tisagenlecleucel (tisa-cel) over axicabtagene ciloleucel (axi-cel). This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

CARBON trial: investigating CTX110 allogeneic CRISPR-Cas9–engineered CAR-Ts in R/R LBCL

Anya Kerkache — Thu, 26 Jan 2023 12:11:30 +0000

Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, St. Vincent’s Hospital, University of Melbourne, Melbourne, Australia, reports results from the CARBON Phase I dose-escalation study (NCT04035434), testing the safety and efficacy of a novel allogeneic CRISPR-Cas9-engineered CAR-T product, CTX110, in heavily pre-treated patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The study reported that the CAR-Ts showed clinical activity with the ability to expand in the body, and a low risk of graft-versus-host disease (GvHD). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Results from the first-in-human trial of huCART19-IL18 in patients with R/R NHL and CLL

Anya Kerkache — Thu, 26 Jan 2023 12:11:27 +0000

Jakub Svoboda, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, describes the mechanism of action of huCART19-IL18, a 4th generation autologous CAR T-cell product, and outlines findings from a first-in-human trial investigating the efficacy of huCART19-IL18 in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphomas (NHL) or chronic lymphocytic leukemia (CLL) (NCT04684563). Results from this study so far have been encouraging, with no unexpected toxicities being recorded and some patients already achieving complete response. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Trials evaluating the efficacy of CD20 CAR-T cell therapy in WM and CNS lymphoma

Anya Kerkache — Thu, 26 Jan 2023 12:11:24 +0000

Mazyar Shadman, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, briefly describes an ongoing multi-center clinical trial investigating the efficacy and safety of CD20 CAR-T cell therapy in patients with Waldenström’s macroglobulinemia (WM) and CNS lymphoma. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

LMY-920 in non-Hodgkin lymphoma

Simon Ng — Mon, 14 Feb 2022 17:40:19 +0000

Patients with B-cell non-Hodgkin lymphoma (NHL) can progress on current anti-CD19 chimeric antigen receptor (CAR) T-cell therapies due to antigen escape. Jeff Liter, MBA, Luminary Therapeutics, Minneapolis, MN, provides an overview of LMY-920, a B-cell activating factor (BAFF)-directed CAR-T therapy, which consists of three different antigens on the CAR T-cell. The three markers prevents antigen escape and the therapy additionally contains no foreign linkers, reducing immunogenicity. An Investigational New Drug Application (IND) will be imminently filed for LMY-920, with the therapy aiming to target NHL and mantle cell lymphoma (MCL). This interview took place at Advanced Therapies Week 2022.

Mechanisms of resistance to CAR T-cell therapies

admin_vjr_user — Tue, 18 Jan 2022 11:12:17 +0000

John Rossi, MS, CERo Therapeutics, San Francisco, CA, discusses mechanisms of resistance and relapse in chimeric antigen receptor (CAR) T-cell therapies. T cells of patients with leukemia, lymphoma or non-Hodgkin lymphoma who have previously received multiple lines of treatment will have a lower proliferative capability and consequently have worse outcomes. Patient response to lymphodepletion therapy, as well as the tumor microenvironment can additionally determine efficacy of CAR T-cell therapies, and tumors can exhibit an immune desert phenotype during relapse, making treatment more difficult. This interview took place at the 2021 CAR-TCR Summit 2021.

Chimeric engulfment receptor (CER) T-cell therapy

admin_vjr_user — Tue, 18 Jan 2022 11:12:16 +0000

John Rossi, MS, CERo Therapeutics, San Francisco, CA, provides an overview of novel chimeric engulfment receptor (CER) T cells which consist of an autologous T cell engineered to express a CER derived from myeloid lineage cells, which can remove diseased or dying cells. CER T-cells behave like chimeric antigen receptor (CAR) T-cells but can enhance antigen presentation of T cells, mediating tumor clearance and inducing a secondary immune response. The technology has the potential to be used in multiple indications including leukemia, lymphoma and solid tumors. This interview took place at the 2021 CAR-TCR Summit 2021.